ELISA is one of the methods the supplier reports using to characterize Bio Xsomes. Request the full analytical documentation rather than a summary result. The method itself is used widely across biology and diagnostics wherever a specific protein needs to be detected and quantified in a sample.
In the context of perinatal tissue and extracellular vesicle products, ELISA panels are one of the methods suppliers use to report which proteins, such as specific growth factors, cytokines or vesicle surface markers, are present in a given lot, and at what measured level. An ELISA result describes what was detected in that assay; it is not evidence of any clinical effect, and growth factor or cytokine panels should be read strictly as analytical findings.
When reviewing an ELISA-based panel from a supplier, check which specific targets were tested, the units and reference ranges used, and whether the results are tied to a specific lot rather than presented as a general product claim. FDA states there are no FDA-approved exosome products; they are generally regulated as biologic drugs under section 351 of the PHS Act, and purchase and clinical-use decisions belong to the physician and their own regulatory counsel.
ELISA data lets a buyer see what proteins were actually measured in a lot, which is useful for documentation review but should not be read as a performance claim.